Biotricity posts first operating profit, revenue +21% amid heavy debt and going-concern

Snapshot - Biotricity Inc. (OTCBB: BTCY)

What's happening inside the company (quick view):
- Revenue momentum: revenue grew to $3,873,993 for Q1 (June 30, 2025) from $3,201,743 a year earlier (≈+21%).
- Mix shift to recurring tech fees: technology fees $3,371,392 (87% of revenue) vs device sales $502,601.
- First quarter ever with positive operating profit: profit from operations $281,945 vs a loss of $(1,116,846) in prior year quarter.
- Cash and operating improvements: cash $391,292 (up from $365,145); net cash used in operating activities improved to $(373,389) from $(1,494,240); Free Cash Flow positive $476,865 for the quarter.
- Still loss-making at the bottom line: net loss attributable to common stockholders $(754,293) for the quarter (loss per share $(0.029)), but materially smaller than prior year $(6,948,292) (loss per share $(0.490)).

Positive aspects (income statement & cash flow)
- Revenue: $3,873,993 (Q1 2025) vs $3,201,743 (Q1 2024).
- Gross profit: $3,116,800 (gross margin 80.5%) vs $2,363,168 (73.8%) - margin expansion +6.7 percentage points.
- Lower operating expenses: Total operating expenses $2,834,855 vs $3,480,014 - SG&A down to $2,138,692 from $2,966,119 (28% reduction).
- Profit from operations: positive $281,945 (first time) - shows core business moving toward profitability.
- EBITDA / Adjusted EBITDA turned positive: EBITDA $333,337 and Adjusted EBITDA $289,368 (prior year negatives).
- Operating cash flow trending better: net cash used in operations improved; the company reported four consecutive quarters of positive Free Cash Flow.

Negative aspects (income statement & balance sheet risks)
- Net loss still present: net loss before dividends $(671,977) and net loss attributable to common $(754,293).
- Heavy financing costs: interest expense $850,254 in the quarter - a material drag on profitability.
- Accretion/amortization volatility: accretion and amortization $153,572 (previously larger), but historically large non-cash financing charges have hit results.
- Large liabilities and leverage: Total liabilities $36,835,946; term loan balance $12,425,131; convertible promissory notes & short-term loans current $10,084,601.
- Working capital and capital structure stress: working capital deficiency ~$16,661,781; stockholders' deficiency $(32,798,917); accumulated deficit $(140,196,078).
- Derivative liabilities and dilution risk: derivative liabilities $1,919,684 (Level 3 fair value) and outstanding convertible/preferred instruments create dilution and mark-to-market volatility.
- Going concern: management discloses substantial doubt about ability to continue as a going concern without additional financing; future financings may be dilutive.

Key balance-sheet and cash statistics
- Cash: $391,292 (June 30, 2025) vs $365,145 (Mar 31, 2025).
- Accounts receivable, net: $1,860,715.
- Inventory: $1,783,426 (finished goods $768,413; raw material $1,015,013).
- Total assets: $6,037,319.
- Current liabilities: $21,806,321; Total liabilities: $36,835,946.
- Term loan (total reported): $12,425,131 (with interest capitalization events noted).
- Derivative liabilities (total fair value): $1,919,684 (short + long term).
- Shares outstanding (Aug 13, 2025): common 26,567,769; exchangeable 160,672 (voting equivalent 26,728,441).

Operational & strategic notes
- Core product commercialization: Bioflux and Biocore sales driving recurring technology fee revenue and higher gross margins.
- R&D is increasing: R&D expense rose to $696,163 - company investing in next-gen devices and AI algorithms (NIH grant activity referenced historically).
- Customer concentration: one customer comprised 23% of receivables at quarter end - concentration risk to monitor.
- Financing activity: issued convertible notes in the quarter and subsequent period (subsequent event: $694,197 issued and $500,000 redeemed). Expect more financings.

What to watch next (short list)
- Cash burn vs new financings: whether management can secure non-dilutive or tolerably priced capital to avoid distress.
- Interest expense and term loan amortization schedule: the high interest cost is the primary headwind to net profitability.
- Conversion/redemption activity: conversions of convertible notes or preferred shares will affect dilution and derivative fair-value volatility.
- Collections and receivable concentration: monitor receivables aging and the one-customer concentration noted (23%).
- Continued margin and revenue mix: will technology-fee recurring growth sustain and expand gross margins further?

Bottom line: Biotricity (OTCBB: BTCY) is showing clear operational progress - revenue growth, materially higher gross margins, the company's first operating profit and positive EBITDA - and improving cash generation. Those positives are counterbalanced by heavy financial leverage, high interest expense, sizeable derivative and debt-related liabilities, a working-capital deficit, ongoing net losses, and an explicit going-concern warning. The near-term outcome hinges on successful financing execution and continued conversion of revenue gains into sustained net profitability.